newsfilter
← Latest News
PR Newswire·

Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance

-- 42% growth in Phexxi® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter -- -- Reduced operating expense by 8% and improved loss from operations by 16% -- -- Completed registrational Phase 3 trial evaluatin